Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Predictive Indicators of Immunosuppressant Combined With Pirfenidone in the Treatment of Connective Tissue Disease-related Interstitial Lung Disease (CTD-ILD)

NCT04928586 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT04928586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04928586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Predictive Indicators of Immunosuppressant Combined With Pirfenidone in the Treatment of Connective Tissue Disease-related Interstitial Lung Disease (CTD-ILD)
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 4
Overall status
Unknown status
Start date
August 16, 2019
Completion date
June 1, 2025
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

connective tissue diseases, interstitial lung disease, pirfenidone